Xenon to Present at Stifel 2025 Virtual CNS Forum

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum, scheduled for March 18-19, 2025. The company will deliver a fireside chat presentation, which will be accessible via live audio webcast on the 'Investors' section of Xenon's website.

Xenon specializes in developing ion channel product portfolio targeting areas with high unmet medical needs, particularly epilepsy and depression. Their leading product, Azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications. This compound represents the most advanced, clinically validated potassium channel modulator in development.

News Market Reaction – XENE

-0.85%

1 alert

-0.85% News Effect

On the day this news was published, XENE declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.

Fireside Chat Presentation Details:

Date:	Wednesday, March 19, 2025
Time:	12:00-12:25 PM Eastern Time
Webcast:	Register here
Presenter:	Dr. Chris Kenney, Chief Medical Officer

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When is Xenon Pharmaceuticals (XENE) presenting at the Stifel 2025 Virtual CNS Forum?

Xenon Pharmaceuticals will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.

What is Xenon's (XENE) lead drug candidate and what does it target?

Azetukalner is Xenon's lead drug candidate, a novel Kv7 potassium channel opener in late-stage clinical development for multiple indications.

Which therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?

Xenon focuses on developing therapeutics for epilepsy and depression through their ion channel product portfolio.

How can investors access Xenon's (XENE) presentation at the Stifel CNS Forum?

Investors can access the live audio webcast of the presentation through the 'Investors' section of Xenon's website, where it will also be available for replay.